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Abstract 
Contamination of surface waters by pharmaceuticals is now widespread. There are few data 
on their environmental behaviour, particularly for those which are cationic at typical surface- 
water pH. As the external surfaces of bacterio-plankton cells are hydrophilic with a net  
negative charge, it was anticipated that bacterio-plankton in surface-waters would  
preferentially remove the most extensively-ionised cation at a given pH. To test this  
hypothesis, the persistence of four widely-used, cationic pharmaceuticals, chloroquine,  
quinine, fluphenazine and levamisole, was assessed in batch microcosms, comprising river- 
water and bacterio-plankton, to which pharmaceuticals were added and incubated for 21 days.  
Results show that levamisole concentrations decreased by 19 % in microcosms containing  
bacterio-plankton, and by 13 % in parallel microcosms containing tripeptide as a priming  
agent. In contrast to levamisole, concentrations of quinine, chloroquine and fluphenazine  
were unchanged over 21 days in microcosms containing bacterio-plankton. At the river-water  
pH, levamisole is 28 % cationic, while quinine is 91-98 % cationic, chloroquine 99 %  
cationic, and fluphenazine 72–86 % cationic. Thus the most neutral compound, levamisole,  
showed greatest removal, contradicting the expected bacterio-plankton preference for ionised  
molecules. However, levamisole was the most hydrophilic molecule, based on its octanol- 
water solubility coefficient (Kow). Overall the pattern of pharmaceutical behaviour within the  
incubations did not reflect the relative hydrophilicity of the pharmaceuticals predicted by the  
octanol-water distribution coefficient, Dow, suggesting that improved predictive power, with  
respect to modelling bioaccumulation, may be needed to develop robust environmental risk  
assessments for cationic pharmaceuticals. 
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1. Introduction 
There are over 4000 pharmaceuticals available for human and veterinary use (Boxall 
et al. 2012). Following administration, unretained pharmaceuticals and any transformation 
products are excreted into surface waters, either directly or via treated and untreated 
wastewaters and biosolids. As a consequence, contamination of aquatic systems by 
pharmaceuticals is now extensive (Hughes et al. 2013; Cizmas et al. 2015). There remains, 
however, a marked lack of knowledge on the aquatic transport and fate of pharmaceuticals, 
and their biological effects (Boxall et al. 2012; Brooks et al. 2012; Kümmerer 2008; LaLone 
et al. 2014; Shore et al. 2014; Tijani et al. 2016). Effects of pharmaceuticals on terrestrial 
organisms have been reported, with one of the most publicised examples being the 
contribution of diclofenac residues to the almost total decline of the Gyps spp. vulture 
populations on the Indian sub-continent (Oaks et al. 2004). While such dramatic effects on 
aquatic organisms have not been reported to date, behavioural changes have been observed. 
For example, environmentally-measured concentrations of the benzodiazepines oxazepam 
and diazepam were shown to markedly alter the social behaviours of the wild European perch 
(Perca fluviatili) and adult zebrafish (Danio rerio), respectively (Brodin et al. 2013; 
Giacomini et al. 2016).  
The prediction of Adverse Outcome Pathways (OECD 2013) for a pharmaceutical 
contaminant is, inter alia, dependent on understanding its mode of action (MoA) giving rise 
to one or more molecular-initiating events within an organism, either through specific ligand-
receptor interactions or non-specific receptor interactions, which then leads to one or more 
adverse effects. Understanding the MoA in theory allows effects predictions to be 
extrapolated to other compounds with similar molecular characteristics, along with the ability 
to ‘read across’ to organisms from different taxonomic groups that share the same receptors 
(Hutchinson et al. 2013). Other important properties relevant to the manifestation of adverse 
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effects include the persistence of, and hence exposure to, the pharmaceutical and the extent of 
accumulation within susceptible biota (Arnold et al. 2014). 
For a given environmental loading, the degree of exposure of an organism to an 
pharmaceutical in surface waters is dependent on the extent of biological and physico-
chemical mechanisms on in situ, measured concentrations of the parent pharmaceutical, and 
any known transformation products. For example, in an assessment of the ability of riverine 
bacterio-plankton to transform the benzodiazepine, diazepam, and its photo-degradation 
product, 2-amino-5-chlorobenzophenone (ACB), diazepam was much more persistent than 
ACB, which was mineralised to ammonium by the bacterio-plankton in all experiments 
(Tappin et al. 2014). This indicated that a removal of diazepam, and other benzodiazepines 
photodegrading to ACB (West & Rowland 2012), could be effected even if the parent 
compound was not readily biotransformed. However, there is a lack of published studies on 
the role of microbes in the environmental cycling of pharmaceuticals, coupled with little 
discussion on biotic mechanisms of pharmaceutical removal. 
In this study, the persistence of a range of commonly-prescribed human and 
veterinary pharmaceuticals in incubations containing riverine bacterio-plankton was 
examined. Chloroquine and quinine are quinoline derivatives used extensively in Asia, Africa 
and South America for the treatment of malaria, although they also have a range of other 
medical applications (Achan et al. 2011; Price et al. 2014); the MoA of their anti-malarial 
properties is not well understood (www.drugbank.ca). Chloroquine is excreted from humans 
either unaltered or as N-desethyl chloroquine, and quinine unaltered or as 3-hydroxyquinine 
(Mirghani et al. 2003; Projean et al. 2003). Fluphenazine is a tri-fluorinated methyl 
phenothiazine derivative used to manage chronic psychoses including schizophrenia (Uchida 
et al. 2011); it is excreted in urine and faeces unchanged, or as 7-hydroxyfluphenazine, 
fluphenazine sulfoxide, and metabolite conjugates (McEvoy et al. 2004). Thus, these 
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compounds will enter surface waters via wastewater discharge and irrigation, and leaching 
from sewage solids applied to land. Concerns regarding the presence of neuroendocrine-
active chemicals in surface waters, and their potential biological effects, have been raised; 
particularly those pharmaceuticals, including fluphenazine, that act on widely conserved 
dopamine receptors (Villeneuve et al. 2010a; Villeneuve et al. 2010b). Levamisole is an 
imidazothiazole derivative used as a human and veterinary anthelmintic (Lanusse et al. 2009). 
It is also used as a human immuno-modulator and as an adulterant in cocaine (Bertol et al. 
2011). For veterinary use, the compound is generally applied topically, thus enhancing its 
transport to surface waters. 
There are no published data on the transformations of these pharmaceuticals in 
surface waters, although it has been predicted that lower than 1 % of the quinine load 
entering a sewage treatment plant would be transformed (Jones et al. 2002). Furthermore, 
there are few data on their toxicity in the aquatic environment. Bioassays using the 
invertebrate Daphnia magna and alga Chlorella vulgaris suggested that chloroquine may be 
harmful to aquatic organisms (Zurita et al. 2005), while fluphenazine showed inhibitory 
effects on a range of bacterial species at concentrations of ca. 40 - 200 µmol L-1 (Dastidar et 
al. 1995). Levamisole has been cited as a high priority compound for detailed environmental 
risk assessment (Capleton et al. 2006; von der Ohe et al. 2011). These pharmaceuticals are all 
included in the World Health Organization's List of Essential Medicines (WHO 2015). 
Furthermore, they are ionisable molecules that can be protonated at surface water pH, and 
there is a paucity of data on the fate of pH-dependent cationic pharmaceuticals in these 
environments.  
The potential problem of environmentally persistent pharmaceutical pollutants was 
recently recognised by the International Conference on Chemicals Management (ICCM 4, 
autumn 2015) as an Emerging Policy Issue of the Strategic Approach to International 
 
6 
 
Chemicals Management (http://www.saicm.org/). Furthermore, 3 pharmaceuticals were 
included on the European Union (EU) watch list of March 2015 (EU 2015), with a view to 
proposing statutory Environmental Quality Standards within the EU Water Framework 
Directive; while the latest United States Environmental Protection Agency draft Contaminant 
Candidate List (CCL4) includes 8 pharmaceuticals and 2 pharmaceutical-precursors 
(https://www.epa.gov/ccl/chemical-contaminants-ccl-4), including quinoline. These 
regulatory concerns reflect the tension between the need for medicines to maintain and 
improve health and managing their potential environmental impact.  
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2. Materials and methods 
The full details of the design, testing and validation of the incubation procedure have 
been reported previously (Tappin et al. 2012; Tappin et al. 2014). 
2.1 Media and chemicals 
River water required for the microcosms and preparation of bacterio-plankton inocula 
were collected from Gunnislake, at the tidal limit of the River Tamar located in southwest 
England, UK. The river drains a rural, agriculture-dominated, catchment, and water quality is 
generally good (Tappin et al. 2012; Tappin et al. 2014), although the river and its catchment 
are impacted by historical metal mining activity. River turbidity is low (generally lower than 
15 mg L-1) and the oxygen saturation is high (generally > 90 %) at the tidal limit, while the 
mean pH is 7.4 (Environment Agency, unpublished data). The pharmaceuticals used in the 
study were purchased as levamisole hydrochloride, quinine hemisulphate monohydrate, 
chloroquine diphosphate and fluphenazine hydrochloride (Sigma Aldrich, AR grade). A tri-
peptide comprising the amino acids glycine, leucine and tyrosine (GLY; Sigma Aldrich, ≥ 98 
% purity), and representing labile organic matter, was also used to assess a priming effect on 
the bacterio-plankton population (Guenet et al. 2010) in the incubations involving levamisole 
only. Stock solutions of these compounds were made up in prepared incubation water and 
stored at 4 ºC in the dark prior to use. Structural details of the compounds are given in Table 
1. 
2.2 Microcosm experiments 
Preparation of incubation water 
River water was filtered (GF/F; 0.7 μm nominal pore diameter) to remove suspended 
particles, passed through a strong anion-exchange resin (Dowex® X-100, 200 mesh; water 
flow rate 80 mL h-1) to remove nitrate, UV-irradiated (400 W medium pressure Hg lamp, 6 h) 
to remove dissolved organic carbon (DOC) and then re-filtered through a 0.2 µm filter 
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membrane (Whatman Anodisc 47, aluminium oxide) to remove any remaining particulate 
matter. These processes reduced nitrate and DOC to concentrations which ensured that 
alternative carbon and nitrogen substrates were, as far as possible, removed and that the river 
water matrix was compatible with direct analysis of samples by electrospray ionisation–mass 
spectrometry (ESI-MS). As a final step, the water was sterilised by autoclaving (115 oC, 15 
min). 
Preparation of the inoculum 
The bacterial inoculum was prepared using river water collected within 24 h prior to 
introduction in to the microcosm. This water was filtered through a 1.6 µm pore diameter 
membrane (combusted GF/A) to remove zooplankton and particle-bound bacterio-plankton 
(Ainsworth & Goulder 1998) and then re-filtered through a 0.2 µm pore diameter membrane 
filter (Whatman Anodisc 47). The bacterio-plankton retained on the membrane was 
resuspended in a small volume of the 0.2 µm filtered water to provide the inoculum, which 
was then added to the pre-treated river water to produce a final, representative bacterio-
plankton concentration. 
Incubation experiments 
Incubation water (60 mL) was transferred to a 125 mL screw-capped amber glass 
bottle to which was added 30 - 60 µL of stock pharmaceutical solution and 1 mL of the 
bacterio-plankton inoculum. Starting concentrations of the compounds were ca. 15-30 μmol 
L-1. Control microcosms of prepared river water containing bacterio-plankton inoculum only 
and the pharmaceuticals only were also set up to account for sorption effects and to 
investigate the effects of the pharmaceuticals on the bacterio-plankton communities. In a 
separate microcosm, 30 μmol L-1 of GLY was added with levamisole. The 125 mL bottles 
were loosely-capped, placed in a re-sealable plastic bag and transferred to an orbital shaker. 
Microcosms were prepared in duplicate at ambient temperature in the dark. An incubation 
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time of 21 days was selected to reflect the river water transit time in the Tamar catchment. At 
day 0 and day 21, incubated samples were filtered using combusted GF/F filters and sub-
samples collected for analyses. 
2.3 Chemical and microbiological analyses 
The pharmaceuticals were analysed by ESI-MS using a Finnegan MAT LCQ MS, a 
quadrupole ion trap mass spectrometer with an external source atmospheric pressure interface 
capable of electro-spray ionisation. Solutions were introduced into the instrument by direct 
injection from a 250 µL Hamilton syringe at a rate of 3 µL min-1. Prior to injection, each 
sample and standard was diluted 1:1 with methanol amended with 0.1 % (v/v) formic acid. 
The signal sensitivity for each pharmaceutical, in positive-ion mode, was optimised by 
adjustment of instrumental parameters using in-built tuning procedures. Ion counts were 
integrated for 2 min, and 5 x 2 min replicates were recorded per sample. Ion count stability 
was followed in real-time via single ion monitoring. Quantitation of the analyte was achieved 
by generating an external standard calibration curve on each analytical day and bracketing 
individual samples with a drift calibration standard to account for variations in instrumental 
sensitivity. Changes in sensitivity were accounted for using an algorithm developed for 
automated nutrient analysis (Skalar Analytical BV 2004); in this implementation baseline 
drift was assumed unimportant (equation 1). 
U’’(n) = (U’(n) * (D1 / ((((D(b) – D(a)) / (b – a)) * (n – a)) + D(a)))                          equation 1 
U’’(n) = drift corrected ion count for sample n, U’(n)  = ion count for sample n, D1 = ion count 
of the first drift standard, D(a) = ion count of the preceding drift standard, D(b) = ion count of 
the following drift standard, n = sample number, a = sample number of preceding drift 
standard and b = sample number of following drift standard. Standards were matrix-matched 
with the water used for the incubations. The identification of m/z values for potential 
biotransformation products was informed by the EAWAG Biocatalysis and Biodegradation 
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Database (EAWAG-BDD; Ellis & Wackett 2012), now redesigned as enviPath (Wicker et al. 
2016). Nitrate + nitrite and orthophosphate were determined by colorimetry with a precision 
of lower than 1 % (Skalar Analytical BV, 2004) and ammonium by o-phthaldialdehyde 
fluorescence with a precision of 4 % (Holmes et al. 1999). 
Viable counts of bacterio-plankton were determined using 100 μL aliquots from the 
incubations. These were diluted in phosphate-buffered saline solution and 100 µL of each 
dilution spread on half strength Luria Bertani agar (Merck, Germany) and incubated at 30 °C 
for two days. Colonies were enumerated as colony forming units (cfu) mL-1 of the original 
suspensions. The extraction of DNA and PCR amplification of 16S ribosomal RNA genes for 
bacterio-plankton community analysis were undertaken on cells retained on a 0.2 µm 
membrane filter. The retained cells were disrupted in a Hybaid Ribolyser™ Cell Disruptor, 
and the DNA was subsequently extracted into hexadecyltrimethylammonium bromide and 
phenol-chloroform-isoamyl alcohol, followed by resuspension in 50 µL nuclease-free water 
(Griffiths et al. 2000). Nested PCR amplifications were performed on these samples using 
Super Taq DNA polymerase (HT Biotech Ltd, UK) and G-Storm thermal cyclers (GRI, UK). 
DNA amplification was undertaken in a 50 μL sample using 1 μmol L-1 of the universal 
primers for eubacterial 16S rRNA genes (27f and 1492r) (Lane 1991) with 1 unit super Taq 
DNA polymerase. The amplified DNA fragments were re-amplified using forward primer 
341 and reverse primer 907 (Muyzer et al. 1995). Denaturing gradient gel electrophoresis 
(DGGE) analysis (Muyzer et al. 1993) was performed on GC-clamped products of the second 
PCR amplification using the Bio-Rad D-code system to separate DNA on a 8 % 
polyacrylamide gel in Tris acetate EDTA buffer (pH 8.0) with a 20-60 % denaturant gradient, 
in which 100 % denaturant was 7 molar urea amended with 40 % formamide (Muyzer et al. 
1993). Electrophoresis was performed at 60 °C, run at 60 V (16 h) and the DNA banding 
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visualised using Sybr Green I stain (Lonza Rockland, USA) with detection and image capture 
on a Storm 860 Molecular Imager (Molecular Dynamics, UK). 
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3. Results and discussion 
3.1 Bacterio-plankton incubations 
The abiotic control studies showed that none of the compounds was lost through 
sorption to the walls of the incubation bottles or through chemical degradation, during the 
experiments. The bacterio-plankton inocula were viable throughout the incubation period, as 
concentrations of colony forming units increased by an order of magnitude in the microcosms 
containing pharmaceuticals (from lower than 10,000 cfu mL-1 at day 0 to 82,000 cfu mL-1 for 
levamisole and 220,000 cfu mL-1 for fluphenazine at day 21). There was also a large increase 
in ammonium concentrations (from 0.7 to 68.0 µmol NH4
+-N L-1) after 21 days in the 
levamisole microcosms to which the GLY peptide had been added (Fig. 1), a further 
indication of bacterio-plankton mineralisation of dissolved organic matter. The NH4
+ 
produced represented ca. 74 % of the peptide nitrogen and its degradation was consistent with 
previous results for such incubations containing GLY only or GLY plus pharmaceutical 
(Tappin et al. 2012; Tappin et al. 2014). In addition, our previous results, using clone 
libraries, showed that bacterio-plankton sampled from the Tamar water microcosms 
contained Gram negative (α-proteobacteria, β-proteobacteria) and Gram positive (Firmicutes) 
groups previously reported for freshwaters, which are capable of biotransforming xenobiotic 
contaminants (Tappin et al. 2014). 
3.2 Persistence of pharmaceuticals 
Between days 0 and 21, the concentration of levamisole decreased from 33.2 μmol L-1 
to 26.9 μmol L-1 (19 % removal) in the biotic incubation (Fig. 1; t-test, p < 0.001, n = 10), 
and to 28.6 μmol L-1 (13 % removal) in the biotic incubation with added peptide (Fig. 1a; t-
test, p = 0.002, n = 10). While solid - solution partition coefficients (Kd) are not available for 
levamisole, Kds for ionisable pharmaceuticals are generally relatively low. The measured 
decreases in dissolved levamisole concentrations were almost certainly due to uptake into the 
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bacterio-plankton, rather than simple sorption to cell surface components as the suspended 
solids concentration was lower than 1 mg L-1 in the incubations. A DGGE fingerprinting of 
the amplified 16S rRNA marker genes of the bacterio-plankton communities incubated with 
and without levamisole, showed that species composition (genotype) profiles were similar 
under all incubation conditions. In contrast to levamisole, the concentrations of quinine, 
chloroquine and fluphenazine remained constant in the microcosms over the 21 day period 
(Fig. 2), indicating that these pharmaceuticals were persistent. 
Passive uptake of low molecular mass (lower than 500) compounds into prokaryotic 
Gram negative and positive bacterio-plankton is more likely to occur with hydrophilic 
moieties, as the outer cell walls of these bacterio-plankton are hydrophilic (Hancock & Bell 
1988; Nikaido & Vaara 1985). They also have a net negative charge which, in principle, 
should favour the electrostatic sorption of positively-charged compounds. The octanol-water 
solubility coefficients (log Kow) of the pharmaceuticals in this study indicate that levamisole 
was the most hydrophilic (Table 2). Their acid dissociation constants (pKa), on the other 
hand, indicate that fluphenazine, chloroquine and quinine would be extensively positively 
ionised at pH 7.4, the mean pH of Tamar river water (Table 2), potentially promoting 
sorption to the cells by electrostatic attraction, while increasing their inherent water solubility 
(Gulde et al. 2014; Rendal et al. 2011a). These physico-chemical characteristics can be 
combined to yield a net hydrophilicity, the octanol-water distribution coefficient (log) Dow, 
which may better explain any observed loss of pharmaceutical from solution (Manallack et al. 
2013; Warhurst et al. 2003). For a monoprotic base (e.g. levamisole), the net hydrophilicity 
can be calculated from equation 2: 
log Dow = log Kow – log [1 + 10
(pK
a 
– pH)]                                                         equation 2 
For a diprotic, basic pharmaceutical (e.g. quinine, chloroquine and fluphenazine), equation 3 
is used, where pKa1 > pKa2: 
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log Dow = log Kow – log [1 + 10
(pK
a1
- pH) + 10(pKa1
+ pK
a2 
- 2pH)]                           equation 3 
The calculated log Dow values at pH 7.4 are given in Table 2. In principle, the smaller the 
value, the more hydrophilic is the compound, and thus the easier for uptake into the cells of 
the bacterio-plankton present in the current study. The results of these calculations suggest 
that chloroquine is the most hydrophilic pharmaceutical, fluphenazine the least, and 
levamisole and quinine intermediate, but this did not correspond with the measured loss of 
pharmaceutical from solution in this study. Similarly poor correlations between estimated log 
Dow and the biotransformation of the basic pharmaceuticals atenolol, ifenprodil and 
propranolol in batch incubations with river water have been reported elsewhere (Yamamoto 
et al. 2009). The lack of predictive power using Dow may be attributed to poorly constrained 
log Kow and / or pKa values, particularly for basic pharmaceuticals (ECETOC 2013; Kah & 
Brown 2008; Manallack et al. 2013). Additionally, it may contribute to our lack of insight to 
the importance of hydrophobic partitioning of ionisable pharmaceuticals relative to possible 
mechanisms of hydrophilic interaction (ECETOC 2013; Manallack et al. 2013). Whatever the 
explanation, an important observation to be drawn from the current study is that it was the 
most hydrophilic pharmaceutical, based on log Kow alone, and least ionised, based on pKa 
alone, that was removed from river water containing bacterio-plankton.  
Studies of pharmaceutical uptake by eukaryotes (animals and plants) have reported 
that it is the non-ionised forms of the pharmaceutical that show greatest partitioning into cells 
(Rendal et al. 2011b; Warhurst et al. 2003) while recently, the extent of bacterial 
transformation of pharmaceuticals incubated with sewage sludge was shown to be generally 
proportional to the fraction of un-ionised, neutral, species present (Gulde et al. 2014). It may 
be concluded, therefore, that of the total pharmaceutical pool present, it is the non-specific 
biotransformation of the neutral or weakly-ionised pharmaceutical fraction that is most likely 
to occur in surface waters, irrespective of cell type. 
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The loss of levamisole did not result in identifiable biotransformation products 
detected by ESI-MS (Fig. 1), even though these were predicted from the EAWAG-BBD, via 
initial de-alkylation of the tertiary amine to yield secondary and primary amines. Indeed, the 
dominance of the observed de-alkylation of pharmaceuticals containing a tertiary amine has 
been reported recently (Gulde et al. 2016). The m/z values of the predicted transformation 
products are marked in Figure 1, and did not correspond with detected peaks. This suggests 
that, if biotransformation molecules were produced, they were not released into solution but 
were further metabolised rapidly, or were present at concentrations below the limit of 
detection under these conditions.  
The 3 pharmaceuticals that were persistent all contain at least one tertiary amine, 
while chloroquine also contains a secondary amine group (Table 1). As noted above, the 
EAWAG-BBD predicts bacterio-plankton alteration of these functional groups via de-
alkylation (Gulde et al. 2016). In contrast, the mono-N-substituted heterocyclic ring in the 
quinolone derivatives quinine and chloroquine is more difficult to decompose (Alexander 
1999), though heterocyclic ring opening of quinoline by bacteria has been reported (Griese et 
al. 2006). The EAWAG-BDD does not take into account the polarity of the molecule under 
consideration, however, and the persistence of these pharmaceuticals is thus probably 
attributable to their extensive (positive) ionisation under the incubation conditions and lack of 
cell uptake; the presumed electrostatic attraction appeared to have no measurable influence 
(Gulde et al. 2014; Rendal et al. 2011a; Rendal et al. 2011b).  While quantitative estimates of 
the relative speeds of cell uptake by ionised and non-ionised basic pharmaceuticals are 
lacking, equivalent studies on acidic moieties show uptake speeds 103–104 lower for the ionic 
forms relative to the neutral species (Rendal et al. 2011b). 
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3.3 Investigation of a priming effect 
The addition of labile organic matter (LOM) to accelerate bacterio-plankton 
biotransformation of more persistent organic matter is known as the priming effect, although 
there are few systematic studies of this phenomenon in aquatic systems (Gontikaki et al. 
2013; Guenet et al. 2014). The presence of LOM, as wastewater effluent DOC added at 
relatively high concentrations, has been proposed to enhance pharmaceutical loss from river 
and estuarine coastal waters (Benotti & Brownawell 2009; Lim et al. 2008), but reports of 
decreased biotransformation of the target molecule, or no change, has also been reported and 
a range of mechanisms has been invoked to explain these varied outcomes (Bengtsson et al. 
2014). In the current work, levamisole was incubated with the peptide as LOM - equivalent to 
ca. 500 µmol C L-1 and ca. 90 µmol N L-1, concentrations which are typical of UK rural and 
semi-rural rivers, and of the same magnitude as the concentrations of DOC reported to 
enhance pharmaceutical loss in surface waters (Benotti & Brownawell 2009; Lim et al. 
2008). While levamisole concentrations decreased in the presence of bacterio-plankton and 
LOM, the loss was not significantly different to that observed in parallel incubations without 
added LOM (t-test, p = 0.142, n = 11). This outcome indicates that the biotransformation of 
levamisole occurs in surface waters, but that there would not necessarily be a priming effect, 
constraining transformation of the molecule to lower than 20 % of the total load. 
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3.4 Environmental implications 
The data from this study suggest that all of the molecules examined would be stable, 
to varying degrees, in surface waters, at least with respect to biotransformation by riverine 
bacterio-plankton. This finding, coupled to their probable continual loading to the 
environment, would suggest they may be persistent or, in the case of levamisole, pseudo-
persistent in surface waters. While it is difficult to contextualise this outcome in relation to 
potential environmental impacts on aquatic organisms due to the absence of data on other 
ameliorating processes (e.g. photo-degradation or sorption to sediments), it may be 
hypothesised that, individually, these compounds will not inflict acute toxic effects at the 
concentrations anticipated. This assessment is supported by the viability of the bacterio-
plankton communities shown in this work, coupled to the lack of community succession 
throughout the incubations for all the pharmaceuticals (indicated by the consistency of the 
DGGE fingerprint patterns across the experiments). Nevertheless, environmental implications 
arising from continual and chronic exposure of aquatic organisms to these pharmaceuticals, 
either as single entities or as mixtures, remain to be addressed. 
Malaria is endemic in the low and low-middle income countries (LLMIC) of Asia, 
Africa and central and South America (http://www.cdc.gov/malaria/about/distribution.html) 
and it is in these regions that use of chloroquine and quinine to combat malaria are likely to 
be highest, and contamination of wastewater with these pharmaceuticals most frequent. Many 
LLMIC make extensive use of wastewater for the irrigation of agricultural and horticultural 
crops, particularly in southern Asia and western South America (Lautze et al. 2014; Lees et 
al. 2016). The implication is that these quinolones will be continually added to surface 
waters, with possibly unforseen environmental consequences given their poorly understood 
modes of action. 
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Dopamine receptors occur in almost all vertebrate and invertebrate animals (Barron et 
al. 2010), while some bacteria and many plant species synthesise dopamine. Unlike in 
animals, the function(s) of, and receptor(s) for, dopamine in plants has yet to be elucidated 
(Kulma & Szopa 2007). The presence in surface waters of dopamine inhibitors like 
fluphenazine and other frequently prescribed behaviour-altering psychiatric and anti-
depressant pharmaceuticals is a cause for concern. It has been reported that the antipsychotic 
pharmaceutical haloperidol, a dopamine inhibitor, may affect the behaviour of some fish 
species (Villeneuve et al. 2010a; Villeneuve et al. 2010b), while benzodiazepenes also 
elucidate behavioural changes in fish (Brodin et al. 2013; Giacomini et al. 2016). If these 
groups of neurotransmitters are persistent in the aquatic environment, then unanticipated and 
undesired impacts may emerge (Brodin et al. 2014). 
The inability to accurately model the bioaccumulation of ionisable pharmaceuticals 
using established physico-chemical metrics, including the compounds examined in this study 
but also more widely, will prevent the development of a robust and comprehensive risk 
assessment of pharmaceutical fate and impact in aquatic systems. Given the projected 
increases in pharmaceutical use across the globe (IMS 2015) it would appear prudent to 
significantly improve our predictive capability with respect to bioaccumulation. 
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4 Conclusions 
This study found that microbially-mediated pharmaceutical loss from river water 
containing bacterio-plankton occurred, to an extent, but only for a pharmaceutical expected to 
be largely un-ionised under the conditions of the experiment. No losses occurred, under 
similar conditions, for the three pharmaceuticals expected to be ionised to a much greater 
degree. This observation is consistent with the paradigm that, in the absence of specific 
uptake mechanisms, small non-polar compounds are more easily sorbed by living cells, 
compared to small polar moieties. The contrasting net hydrophilic values calculated for the 
pharmaceuticals indicated that the explanation is less straightforward, although some of the 
data underpinning the calculations may not be well constrained. Thus, an improved predictive 
bacterio-plankton cell uptake capability for ionisable cationic pharmaceuticals in aquatic 
systems would appear to be imperative. 
Although studies of pharmaceuticals in surface waters of high income countries is 
now in its fourth decade, their remains little systematic understanding of pharmaceutical 
transport, fate and impact. This is all the more concerning for lower income countries, where 
pharmaceutical use is forecast to increase significantly in the foreseeable future, with 
attendant increased losses of pharmaceuticals to the environment, and losses in many cases 
fuelled by the aspiration for the increased use of waste water for the irrigation of agricultural 
and horticultural crops. This will only enhance the widespread diffuse contamination of 
aquatic systems by pharmaceuticals, with potential unforeseen consequences.
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Table 1: Structural information on the compounds studied. 
Compounda IUPAC namea CAS No. Structurea 
peptide 
(C17H27O5N3) 
Glycyl-L-leucyl-L-tyrosine 4306-24-5 
 
Chloroquine 
diphosphate 
(C18H26ClN3) 
N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine 50-63-5 
 
quinine hemisulfate 
monohydrate 
(C20H24N2O2)a 
(R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-
2-yl)methanol 
303137-00-0 
 
fluphenazine 
hydrochloride 
(C22H26F3N3OS) 
2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-
yl]propyl]-piperazin-1-yl]ethanol 
69-23-8 
 
levamisole 
hydrochloride 
(C11H12N2S)a 
(6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole 16595-80-5  
 
a Main molecule only.
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Table 2: Acid dissociation constant (pKa)
a, octanol-water solubility co-efficient (log Kow)
a 
and octanol-water distribution co-efficient (log Dow) data for chloroquine, quinine, levamisole 
and fluphenazine. Calculated extent of pharmaceutical ionisation is also shown. 
 
 
a These data include both measured and predicted values, and were obtained from 
www.drugbank.ca and references/links given within 
b Calculated from:  
1
1+10−1(𝑝𝐻−𝑝𝐾𝑎1)
 (ECETOC, 2013) 
c Environment Agency of England, unpublished data 
d Calculated from equations 2 and 3 in the text 
 
 pKa1 pKa2 log Kow % Ionised
b 
(at pH 7.4c) 
log Dow
d 
(at pH 7.4c) 
Chloroquine 9.94 – 10.87 7.44 – 8.50 3.93 – 5.28 > 99 -0.67 – 2.42 
Quinine 8.4 – 9.05 4.13 – 4.32 2.51 – 3.44 91 - 98 0.85 – 2.40 
Levamisole 6.98  1.84 – 2.36 28 1.70 – 2.22 
Fluphenazine 7.84 – 8.21 3.98 3.97 – 4.4 72 - 86 3.10 – 3.83 
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Figure 1: (a) Concentrations of levamisole, ammonium, nitrate+nitrite and orthophosphate in 
each microcosm at days 0 and 21. 1, t = day 0; 2, t = day 21 abiotic control; 3, t = day 21 
bacterio-plankton + levamisole; 4, t = day 21 bacterio-plankton + levamisole + labile organic 
matter. Error bars represent ± 1σ of the results from duplicate incubations with each sample 
analysed 3–5 times (n = 6–10). < LoD, lower than limit of detection. Concentrations of 
levamisole were reduced by 19 and 13 % in incubations 3 and 4, respectively. (b) Ion 
chromatograms (relative abundance of ion (%) vs. m/z) of levamisole in solution in a standard 
(left panel) and at day 21 (right panel). The horizontal bar shows the range in m/z values of 
possible transformation products predicted by the EAWAG Biocatalysis and Biodegradation 
Database.  
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Figure 2: Concentrations of (a) fluphenazine, (b) quinine and (c) chloroquine in each 
microcosm at days 0 and 21. 1, t = day 0; 2, t = day 21 abiotic control; 3, t = day 21 bacterio-
plankton plus pharmaceutical. Error bars represent ± 1σ of the results from duplicate 
incubations with each sample analysed five times (n = 10). Concentrations of the 
pharmaceuticals were not significantly different after 21 days under the different incubation 
conditions. 
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